Early norepinephrine not associated with 24-hour mortality among blunt trauma, hemorrhagic shock patientsStudy adds to the debate about use of vasopressors for these patients. Common cardiovascular drugs and Paxlovid can cause drug-drug interactions: review People who are taking common cardiovascular drugs and given Paxlovid (nirmatrelvir/ritonavir) are at risk of drug-drug interactions, according to a review in the Journal of the American College of Cardiology. Health Canada approves two therapies for COVID-19 treatment Single-dose Evusheld is now indicated for treating mild/moderate COVID-19 and Actemra IV is now approved for treating COVID-19 in hospitalized adults. Type 2 Diabetes medication update Selecting medications to manage hyperglycemia . . . and comorbidities, DOAC dosing in older patients with nonvalvular atrial fibrillation An oral anticoagulant is recommended for most patients aged ≥ 65 years with nonvalvular atrial fibrillation (NVAF), to reduce the risk of stroke. Aspirin may benefit people with elevated lipoprotein-a (Lp(a)) Recognized as an independent risk factor for cardiovascular disease, there are no approved therapies. Alberta pharmacists develop DOAC drug interactions management resource Practice a tool compares drug interactions with the four marketed DOACs, focusing on interactions commonly encountered in thrombosis/cardiology-based practices New Canadian guideline for using GLP-1 agonists and SGLT2 inhibitors for cardiorenal risk reduction GLP-1 receptor agonists and SGLT2 inhibitors have proven cardiorenal benefits in patients with and without type 2 diabetes. QUIZ: Vascular anomalies in childhood Do you know when and how to treat hemangiomas, and when to refer? Update to Canadian guidelines on managing pediatric dyslipidemia Provide an approach to the detection, evaluation and management of dyslipidemia in children and adolescents. First Previous 16 17 18 19 20 Next Last
